Phase I trial of anti HER2 antibody toxin conjugate [Zemab] for the treatment of HER2 positive head & neck cancer and breast cancer

Trial Profile

Phase I trial of anti HER2 antibody toxin conjugate [Zemab] for the treatment of HER2 positive head & neck cancer and breast cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jun 2008

At a glance

  • Drugs Anti-HER2 antibody-toxin conjugate (Primary)
  • Indications Breast cancer; Head and neck cancer
  • Focus Adverse reactions
  • Sponsors TopoTarget
  • Most Recent Events

    • 24 Jun 2008 New trial record.
    • 14 May 2008 This study has been completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top